If you’re an AP Computer Science student using CodeHS, you’re about to get a significant upgrade: the platform is refreshing its Python curriculum for Fall 2026 with improved autograders, clearer ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion is more than a coding trick—it’s a powerful way to simplify complex problems in Python. From elegant tree traversals to backtracking algorithms, mastering recursion opens the door to cleaner ...

Anthropic’s Claude agents outperformed human researchers and produced “alien science,” raising new questions about AI alignment and self-improvement.

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Getting ready for coding interviews can feel like a big task, and figuring out the best way to tackle LeetCode is a common question. Many people find that using Python for their LeetCode solutions ...

We recently published 12 Best Healthcare Stocks to Buy Under $30. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best healthcare stocks. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a ...

Recursion said today it is eliminating approximately 20% of its workforce—about 160 jobs—in a restructuring the AI-based drug developer said reflects both its recently-pruned pipeline and the ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...

The overall stock market decline likely weighed on Recursion's shares. CNBC host Jim Cramer's recent hesitation about the biotech stock could also be causing angst for investors. Part of the reason ...